VIR-2218 and VIR-3434 with or without Pegylated Interferon Alfa-2a for the Treatment of Chronic HBV Infection: End-of-Treatment Results After 24 Weeks of Therapy (MARCH Study Part B)

Conference Reports for NATAP

AASLD
The Liver Meeting
November Fri, Nov 10, 2023 - Mon, Nov 14, 2023


VIR-2218 and VIR-3434 with or without Pegylated Interferon Alfa-2a for the Treatment of Chronic HBV Infection: End-of-Treatment Results After 24 Weeks of Therapy (MARCH Study Part B)

	AASLD 2023 nov 10-14 https://www.aasld.org/the-liver-meeting